Jantovia-Mxr 50/500mg Tablet

Jantovia-Mxr 50/500mg Tablet is a medication that combines two active ingredients: sitagliptin & metformin. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while metformin is a biguanide antidiabetic agent. This tablet is formulated to help manage type 2 diabetes mellitus by addressing various aspects of glucose regulation.

Uses:

Jantovia-Mxr 50/500mg Tablet is prescribed for the following purposes:

1. Controlling blood sugar levels in individuals with type 2 diabetes mellitus.
2. Improving glycemic control when used alongside dietary changes and exercise.
3. Lowering hemoglobin A1c (HbA1c) levels, indicating long-term glucose control.
4. Preventing complications associated with uncontrolled diabetes, such as cardiovascular disease and neuropathy.

Side Effects:

Although Jantovia-Mxr 50/500mg Tablet is generally well-tolerated, some individuals may experience the following side effects:

1. Nausea and vomiting
2. Diarrhea
3. Abdominal discomfort or pain
4. Headache
5. Hypoglycemia (low blood sugar) when used with other antidiabetic medications
6. Upper respiratory tract infections

It is important to consult a healthcare professional if any adverse reactions occur.

Precautions:

Before using Jantovia-Mxr 50/500mg Tablet, consider the following precautions:

1. Inform your doctor about any pre-existing medical conditions, especially kidney or liver problems.
2. Use caution in elderly patients as they may be more prone to lactic acidosis, a rare but serious side effect associated with metformin.
3. Regular monitoring of kidney function and blood glucose levels is recommended during treatment.
4. Limit alcohol intake while taking this medication as it may increase the risk of lactic acidosis.
5. Inform your healthcare provider about all other medications, including over-the-counter drugs and supplements, to avoid potential drug interactions.

When Not to Use:

Avoid using Jantovia-Mxr 50/500mg Tablet in the following circumstances:

1. Known hypersensitivity or allergy to sitagliptin, metformin, or any of the tablet’s components.
2. Severe kidney impairment (creatinine clearance <30 mL/min) or end-stage renal disease.
3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
4. History of lactic acidosis or predisposing factors such as heart failure or respiratory insufficiency.
5. Pregnancy or breastfeeding, unless the potential benefits outweigh the risks and under medical supervision.

In conclusion, Jantovia-Mxr 50/500mg Tablet is an effective combination medication for managing type 2 diabetes mellitus. When used as directed under medical supervision, it helps control blood sugar levels and reduces the risk of diabetes-related complications.